Celsion Corporation

425 articles with Celsion Corporation

• Celsion Corporation Announces Company Name Change to Imunon, Inc.

  9/19/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases.

• Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

  9/15/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company’s IL-12 gene-mediated immunotherapy.

• Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13

  9/12/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time.

• Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  Celsion Corporation, a clinical-stage drug development company announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference.

• Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

  9/1/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform technology.

• Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update

  8/15/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three and six months ended June 30, 2022.

• Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

  8/8/2022

  Celsion Corporation announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs.

• 

  BioSpace Movers & Shakers: National Cancer Institute, Evelo, Eagle, ROME & More

  7/22/2022

  Companies from across the life sciences added new executive and financial leaders, as well as scientific and regulatory additions. Here are this week's Movers & Shakers. 

• Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

  7/19/2022

  Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 177,000 shares of common stock, and (ii) restricted stock grants.

• Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

  7/19/2022

  Celsion Corporation (NASDAQ: CLSN ), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Company’s Board of Directors has appointed biopharmaceutical leader Corinne Le Goff, Pharm D, MBA, as President and Chief Executive Officer and Director, effective July 18, 2022.

• Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update

  5/16/2022

  Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the quarter ended March 31, 2022, and provided an update on its clinical development program.

• Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

  5/10/2022

  Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, provided an update on the progress made in the Company’s two lead development programs.

• Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

  5/9/2022

  Celsion Corporation announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to discuss financial results for the first quarter ended March 31, 2022 and provide an update on product development programs.

• Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

  4/21/2022

  Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today presented its PLACCINE platform technology at the World Vaccine Congress taking place in Washington D.C.

• Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

  4/14/2022

  Celsion Corporation and Medidata today announced that they presented their findings on the use of a Synthetic Control Arm Ⓡ (SCA) in a completed Phase Ib dose-escalating study of GEN-1 in the neoadjuvant treatment of patients with Stage III/IV ovarian cancer.

• Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

  4/12/2022

  Celsion Corporation today announced it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine Congress taking place in Washington D.C. on April 18-21, 2022.

• CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

  4/6/2022

  Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase price of $5.27 per share in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of $7.0 million before deducting placement agent fees and expenses.

• Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

  4/6/2022

  Celsion Corporation (NASDAQ: CLSN) and Medidata, a Dassault Systèmes company, today announced that they will be presenting their findings on the use of a Synthetic Control ArmⓇ (SCA) in a completed Phase Ib dose-escalating study of GEN-1 in the neoadjuvant treatment of patients with Stage III/IV ovarian cancer (the OVATION 1 Study) at the Annual Meeting of the American Association for Cancer Research.

• Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021

  4/1/2022

  Celsion Corporation  today announced the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings announcement on March 31, 2022.

• Celsion Corporation Reports 2021 Financial Results and Provides Business Update

  3/31/2022

  Celsion Corporation today announced financial results for the year ended December 31, 2021, and provided an update.